

May 16, 2023

FOR IMMEDIATE RELEASE

Company name	Resorttrust, Inc.
Representative	Ariyoshi Fushimi, President
Code	4681, First Section of the Tokyo and Nagoya Stock Exchanges

**Cancer Intelligence Care Systems, Inc. (Consolidated Subsidiary of Resorttrust, Inc.)**  
**and Edogawa Hospital Enter Agreement to Conduct Specified Clinical Research**

Resorttrust, Inc. (“the Company”) announces that its consolidated subsidiary, Cancer Intelligence Care Systems, Inc. (“CICS”; President, Tetsuya Furukawa; headquarters, Koto-ku, Tokyo), has entered into an agreement to collaborate in investigator-initiated specified clinical research\* (“the Research”) targeting recurrent breast cancer. CICS will cooperate in the Research, which is to be conducted at Edogawa Hospital (Edogawa-ku, Tokyo), by providing technology related to a neutron irradiation device for boron neutron capture therapy (BNCT).

The purpose of the Research is to evaluate the safety and efficacy of BNCT in the treatment of breast cancer that recurs after radiotherapy. Those patients who have recurrent breast cancer, specifically tumor recurrence after radiotherapy, will be eligible.

Edogawa Hospital is equipped with a neutron irradiation device that CICS has installed and is developing at National Cancer Center Hospital. In the Research, this device will be used in combination with boron compounds for BNCT developed by STELLA PHARMA CORPORATION (Chuo-ku, Osaka).

CICS supports the intent of the Research and will provide technology related to CICS’s neutron irradiation device for BNCT. The impact this project has on the Company’s consolidated business performance will be immaterial.

Breast cancer that recurs after radiotherapy often cannot be treated surgically, nor can it be treated with conventional radiotherapy, as radiotherapy cannot be readministered to the same area. For this reason, primary treatments are chemotherapy and hormone therapy, but these have side effects and are not able to treat the root cause that would completely cure the disease. Since BNCT is a treatment method that selectively kills cancer cells, it is unique in that it can be applied to sites that have been irradiated in the past, leading to expectations that BNCT will become a new treatment option.

The Resorttrust Group entered the medical business in 1994, beginning its membership-based medical club. For cancer screening, the Group introduced positron emission tomography (PET), which at the time was used for research conducted at Yamanakako Clinic. In addition to greatly contributing to the spread of PET in Japan, it has helped to promote research activities with university hospitals in fields such as image diagnosis and preemptive medicine. Today, the Resorttrust Group is not only involved in screening but is also expanding treatment solutions, supporting the operation of facilities providing advanced cancer immunotherapy.

Based on the brand identity of “Together for a Wonderful Life” the Resorttrust Group has as its slogan “contributing to the age of 100-year life spans (wellbeing).” Furthermore, reflecting the Group’s hope to create a society where cancer claims no precious lives, it has engaged in cancer screening and treatment. Through our initiatives with BNCT, together with helping to create a more affluent, happy time, we hope to bring new light to cancer treatment.

\*About clinical research

The term “clinical trials,” as defined by the Clinical Trials Act, “refers to research to clarify the efficacy or safety of pharmaceuticals by the use of such pharmaceuticals in humans” (excluding those falling under clinical trials and other research specified by an Ordinance of the Ministry of Health, Labour and Welfare).

The term “specified clinical research” refers to clinical research that is conducted under the auspices of a pharmaceutical marketing authorization holder or its special related party (i.e., subsidiary) (limited to clinical research that uses pharmaceuticals manufactured and sold or intended to be manufactured and sold by the said manufacturer or distributor) or clinical research that uses drugs not yet approved of or that are off label.

\*Reference: Ministry of Health, Labour and Welfare “About Clinical Trials Act”

### About BNCT

Boron neutron capture therapy (BNCT), a form of radiotherapy, is a new method of treating cancer.

When patients receive a boron agent, a boron compound ( $^{10}\text{B}$ ) accumulates in their cancer cells. The area of the tumor is then exposed to an external source of extremely low-energy neutron radiation, which while having little effect on the human body, causes the boron ( $^{10}\text{B}$ ) to capture neutrons, resulting in a reaction that causes the release of alpha rays and  $^7\text{Li}$  nuclei. BNCT is therefore a medical treatment that leverages radiation to selectively kill cancer cells.

In addition, in principle, as treatment is completed with a single neutron irradiation, expectations are for this to be a treatment that causes little damage to the body.

### About the CICS neutron capture therapy device

This is an accelerator-based neutron capture therapy device developed by CICS. It produces neutrons by bombarding a lithium target with protons which are accelerated by a Radio Frequency Quadrupole (RFQ) linear accelerator. CICS-1 is notable for the low level of contamination of fast neutrons, which are detrimental to the human body. The neutrons produced have a low energy level of 800keV or less, facilitating the miniaturization of the moderator used to slow the neutrons down to around 10keV, a level suitable for BNCT.